Please try another search
Concert Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company that develops novel small-molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in a Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It provides data from the first Phase 3 clinical trial, THRIVE-AA1, to form the basis of a new drug application. The company was incorporated in 2006 and is based in Lexington, Massachusetts. As of March 6, 2023, Concert Pharmaceuticals, Inc. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review